Location: Canada, Ontario, London
Total raised: $14.2M
Investors 2
| Date | Name | Website |
| 29.01.2023 | Bantam Gro... | bantamgrou... |
| - | Esperante | esperante.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.12.2022 | Grant | $14.2M | - |
Mentions in press and media 19
| Date | Title | Description |
| 24.11.2022 | LumiraDx Launches Rapid Microfluidic Immunoassay C-Reactive Protein Test to Help Combat Antimicrobial Resistance in India | Mumbai, Maharashtra, India The LumiraDx CRP diagnostic test combines speed and test sensitivity at the point of need, empowering doctors to make informed decisions on antibiotic prescriptions 1,2, The test provides actionable results to car... |
| 15.11.2022 | Using Point of Care Testing to Transform Patient Care in General Practice and Primary Care Networks, Upcoming Webinar Hosted by Xtalks | With the National Health Service (NHS) committing to a target of becoming net zero by 2045³, the speakers will explore how the implementation of point of care testing within primary care can assist in reaching this goal. TORONTO (PRWEB) Nov... |
| 14.11.2022 | LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test | Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa Early customers include GP offices and other community-based healthcare settings Latest figures, released as part of World Diabetes Day, reveal that 1 in 10 ... |
| 09.11.2022 | Supporting Antimicrobial Stewardship Using Point of Care CRP Testing, Upcoming Webinar Hosted by Xtalks | Tackling AMR requires a multi-faceted approach and research has shown how incorporating CRP (C-reactive protein) testing into clinical practice may help to limit antibiotic use to only those patients with severe bacterial infections and the... |
| 29.07.2022 | Transforming Point-of-Care Diagnostic Testing, Upcoming Webinar Hosted by Xtalks | Next-generation POC testing, different from traditional lateral flow tests, is proving its ability to deliver highly sensitive testing with actionable test results within minutes. TORONTO (PRWEB) July 29, 2022 Advancements in point-of-care ... |
| 14.01.2022 | LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant | Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test detects Omicron at a comparable sensitivity to other variants LONDON, Jan. 14, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generatio... |
| 27.12.2021 | DIGIT’s Biggest Scottish Deals of 2021 | Despite a difficult two years due to the pandemic and the impact of Brexit, Scottish companies have continued to see strong growth and gain access to extra funding. Sectors such as banking, e-commerce, space and life sciences all saw substa... |
| 10.11.2021 | LumiraDx Reports Third Quarter 2021 Financial Results | LONDON, Nov. 10, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for the quarter ended September 30, 2021. Revenue of $109.1M for the three months end... |
| 20.10.2021 | LumiraDx : receives approval for its COVID-19 Antigen Test for use in India | LONDON, Oct. 20, 2021 /PRNewswire/ -- Today, LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics testing company announced it has received emergency use approval by India's Central Drugs Standard Control Organisation for it... |
| 20.10.2021 | LumiraDx Receives Approval for its COVID-19 Antigen Test for use in India | London, United Kingdom Test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of COVID-19 LumiraDx’s microfluidic technology and innovative Point of Care (POC) Platform supports a... |
Show more